Generalized Pairwise Comparisons

[1]  M. Buyse.  Generalized pairwise comparisons of prioritized outcomes in the two‐sample problem , 2010, Statistics in medicine.

[2]  M. Buyse,et al.  Reformulating the hazard ratio to enhance communication with clinical investigators , 2008, Clinical trials.

[3]  S. Senn.  U is for Unease: Reasons for Mistrusting Overlap Measures for Reporting Clinical Trials , 2011 .

[4]  M. Kieser,et al.  A weighted combined effect measure for the analysis of a composite time‐to‐first‐event endpoint with components of different clinical relevance , 2018, Statistics in medicine.

[5]  M. Buyse,et al.  The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials. , 2016, JAMA oncology.

[6]  Xiaodong Luo,et al.  Weighted win loss approach for analyzing prioritized outcomes , 2017, Statistics in medicine.

[7]  B. Davis,et al.  Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint. , 1992, Statistics in medicine.

[8]  M. Vandemeulebroecke,et al.  A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components , 2016, Pharmaceutical statistics.

[9]  R. Grissom.  Probability of the superior outcome of one treatment over another. , 1994 .

[10]  D. Schoenfeld,et al.  Global rank tests for multiple, possibly censored, outcomes , 2016, Biometrics.

[11]  R. Stine,et al.  Non-parametric estimates of overlap. , 2001, Statistics in medicine.

[12]  L. A. van der Ark,et al.  Comment on Thas, De Neve, Clement and Ottoy (2012): Probabilistic index models , 2012 .

[13]  M. Buyse,et al.  An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring , 2018, Statistical methods in medical research.

[14]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Lachin,et al.  Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. , 2016, Biostatistics.

[16]  Margaret S Pepe,et al.  Using the ROC curve for gauging treatment effect in clinical trials , 2006, Statistics in medicine.

[17]  M. Buyse,et al.  Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer , 2015, British Journal of Cancer.

[18]  L. Clement,et al.  An extension of the Wilcoxon-Mann-Whitney test for analyzing RT-qPCR data , 2013, Statistical applications in genetics and molecular biology.

[19]  D. Schoenfeld,et al.  Combining mortality and longitudinal measures in clinical trials. , 1999, Statistics in medicine.

[20]  W. Tsai,et al.  An alternative approach to confidence interval estimation for the win ratio statistic , 2015, Biometrics.

[21]  D. Oakes.  On the win-ratio statistic in clinical trials with multiple types of event , 2016 .

[22]  S. Pocock,et al.  The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities , 2011, European heart journal.

[23]  L. Clement,et al.  Probabilistic index models , 2012 .

[24]  D. Rom,et al.  Testing for individual and population equivalence based on the proportion of similar responses. , 1996, Statistics in medicine.

[25]  P S Romano,et al.  Confidence interval estimates of an index of quality performance based on logistic regression models. , 1997, Statistics in medicine.

[26]  W. Brannath,et al.  Opportunities and challenges of combined effect measures based on prioritized outcomes , 2014, Statistics in medicine.

[27]  M. Buyse,et al.  An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma , 2016, Oncotarget.

[28]  Duolao Wang,et al.  The stratified win ratio , 2018, Journal of biopharmaceutical statistics.

[29]  James G Krueger,et al.  Combining several ordinal measures in clinical studies , 2004, Statistics in medicine.